

A Global Definition of Patient Blood Management

Aryeh Shander, MD,*† Jean-Francois Hardy, MD,‡§ Sherri Ozawa, RN,†|| Shannon L. Farmer, DHSc,¶##†† Axel Hofmann, Dr.rer.medic,¶**‡‡ Steven M. Frank, MD,§§ Daryl J. Kor, MD,|||¶¶ David Faraoni, MD,§## and John Freedman, MD,***††† Collaborators

While patient blood management (PBM) initiatives are increasingly adopted across the globe as part of standard of care, there is need for a clear and widely accepted definition of PBM. To address this, an expert group representing PBM organizations, from the International Foundation for Patient Blood Management (IFPBM), the Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (NATA), the Society for the Advancement of Patient Blood Management (SABM), the Western Australia Patient Blood Management (WAPBM) Group, and OnTrac (Ontario Nurse Transfusion Coordinators) convened and developed this definition: "Patient blood management is a patient-centered, systematic, evidence-based approach to improve patient outcomes by managing and preserving a patient's own blood, while promoting patient safety and empowerment." The definition emphasizes the critical role of informed choice. PBM involves the timely, multidisciplinary application of evidence-based medical and surgical concepts aimed at screening for, diagnosing and appropriately treating anemia, minimizing surgical, procedural, and iatrogenic blood losses, managing coagulopathic bleeding throughout the care and supporting the patient while appropriate treatment is initiated. We believe that having a common definition for PBM will assist all those involved including PBM organizations, hospital administrators, individual clinicians and policy makers to focus on the appropriate issues when discussing and implementing PBM. The proposed definition is expected to continue to evolve, making this endeavor a work in progress. (Anesth Analg 2021;00:00–00)

GLOSSARY

AABB = Association for the Advancement of Blood & Biotherapies; **ABC** = Anemia, Blood loss and Coagulopathy; **AMsect** = American Society of Extracorporeal Technology; **ANH** = acute normovolemic hemodilution; **ASA** = American Society of Anesthesiologists; **ASPB** = Asia-Pacific Society for Patient Blood Management; **AWGE** = Anemia Working Group Spain; **BMS** = Bloodless Medicine and Surgery; **COX2** = cyclooxygenase-2; **CSPBM** = Chinese Society for Patient Blood Management; **DOACs** = direct oral anticoagulants; **Fio₂** = fraction of inspired oxygen; **GI** = gastrointestinal; **Hb** = hemoglobin; **IFPBM** = International Foundation for Patient Blood Management; **KPBM** = Korean Society for Patient Blood Management; **KSA** = Korean Society of Anesthesiologists; **MSH** = Malaysian Society of Haematology; **NAS PBM** = National Association of Patient Blood Management Specialists Russia Federation; **NATA** = Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis; **NSAID** = nonsteroidal anti-inflammatory drug; **ONTrac** = Ontario Nurse Transfusion Coordinators; **PBM** = patient blood management; **PCC** = prothrombin complex concentrate; **PPI** = proton-pump inhibitor; **RCT** = randomized controlled trial; **SABM** = Society for the Advancement of Blood Management; **SANBS** = South African National Blood Service; **SCA** = Society of Cardiovascular Anesthesiologists; **SOP** = standard operating procedure; **WAPBM** = Western Australia Patient Blood Management; **WBC** = white blood cell; **WHO** = World Health Organization

From the *Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Health, Englewood, New Jersey; †Society for the Advancement of Patient Blood Management (SABM), Mount Royal, New Jersey; ‡Department of Anaesthesiology and Pain Medicine, Université de Montréal, Montréal, Quebec, Canada; §Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (NATA), Paris, France; ||Institute for Patient Blood Management and Bloodless Medicine and Surgery, Englewood Health, Englewood, New Jersey; ¶Medical School and Division of Surgery, Faculty of Medicine and Health Sciences, The University of Western Australia, Perth, Western Australia, Australia; #Department of Haematology, Royal Perth Hospital, Perth, Western Australia, Australia; **International Foundation for Patient Blood Management, Basel, Switzerland; ††The Western Australia Patient Blood Management Group, The University of Western Australia, Perth, Western Australia, Australia; ##Department of Anesthesiology, University Hospital Zurich, Zurich, Switzerland; §§Department of Anesthesiology, Critical Care Medicine, Johns Hopkins Health System Patient Blood Management Program, The Copyright © 2022 International Anesthesia Research Society

DOI: 10.1213/ANE.00000000000005873

Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, Maryland; |||Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Michigan; ¶¶Patient Blood Management Program, Mayo Clinic, Rochester, Michigan; ##Department of Anesthesiology, Hospital for Sick Children, Toronto, Ontario, Canada; ***Ontario Nurse Transfusion Coordinators Program (ONTrac), Ontario, Canada; and †††The Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Accepted for publication August 9, 2021.

Funding: None.

Conflicts of Interest: See Disclosures at the end of the article.

A full list of contributors can be found at the end of the article.

Reprints will not be available from the authors.

Address correspondence to Aryeh Shander, MD, Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, 350 Engle St, Englewood, NJ 07631. Address e-mail to aryen.shander@teamhealth.com.

Several patient blood management (PBM) initiatives are being developed and implemented across the globe. While most tend to agree on the general principles governing PBM, lack of a clear, widely accepted definition may affect consistent implementation of PBM in different clinical settings. A definition is “a statement expressing the essential nature of something.” This is important because it enables us to have a common understanding of the subject; and for all to be on the same page when discussing or reading about an issue. The purpose of a definition is to explain the meaning of a term that may be obscure or difficult, using terms that are commonly understood and whose meaning is clear. Definitions and terms serve as descriptors of care, and can help shape practice, education, and research. They also provide a framework for practice and a basis for collaboration and growth. As a diverse group with a common interest in PBM, our efforts in the field of interest have been hampered by the use of various terms and definitions, often used to emphasize one aspect in particular of PBM or a specific therapeutic intervention. Such intervention-focused definitions are limited in contributing to improved practice and patient outcomes. Therefore, an inclusive but concise definition will provide exact statements that can be used to define practice and lead to benchmarking and performance enhancement.

To address this, an expert group representing PBM organizations, from the International Foundation for Patient Blood Management (IFPBM), the Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (NATA), the Society for the Advancement of Patient Blood Management (SABM), the Western Australia Patient Blood Management (WAPBM) Group, and ONTraC (Ontario Nurse Transfusion Coordinators), convened under the Global Definition Group, have been working to develop a global definition of PBM. SABM and NATA produced an initial draft that was discussed in person and by e-mail with the IFPBM and WAPBM groups. Once all had submitted suggestions and agreed on the proposed definition, endorsement by other relevant PBM organizations was sought.

BACKGROUND AND EVOLUTION OF PBM

Before the advent of allogeneic blood transfusion as a widely available and commonplace procedure, clinicians faced with patients at risk of bleeding and anemia often utilized effective strategies to manage and preserve a patient's own blood by treating anemia and giving meticulous attention to preventing and stopping bleeding.^{1,2} Anemia had to be prevented and mitigated as transfusion was not an option.

With the emergence of transfusion medicine in the early 20th century, physicians found a quick and easy

treatment that seemed to make the prior strategies of treating anemia and bleeding obsolete. Allogeneic blood transfusions were described as “life-saving” and became one of the most common but also over-used invasive procedures performed in hospitals. Use of the term “life-saving” illustrates how terminology can influence practice.³

In the early 1960s, in what would become a paradigm shift in practice,⁴ renowned cardiovascular surgeon Dr Denton Cooley pioneered what would come to be known as “bloodless surgery” to accommodate Jehovah's Witness patients' request for treatment without allogeneic transfusion. In doing so, his team applied one of the fundamental elements of evidence-based medicine, namely, “the integration of best research evidence with clinical expertise and patient values and preferences.”⁵ At a time when cardiovascular surgeries were notorious for their dependence on large volumes of allogeneic blood, Cooley et al⁶ team adopted a 3-step approach: optimizing the patient's red cell mass preoperatively, utilizing surgical, anesthetic, and pharmacological techniques to minimize blood loss, and tolerating postoperative anemia. These would later evolve into the “three pillars of PBM.”⁷ Cooley^{6,8,9} reported on over 12,000 surgeries without transfusion with positive patient outcomes.

Other clinicians adopted this approach, expanding modalities and techniques, some old, some new,^{10,11} to manage and preserve the patient's own blood and accommodate patient choice. Modalities included erythropoietic support to increase hemoglobin (Hb) level, blood loss (related to surgical, procedural, and laboratory sampling as well as coagulopathies) minimized, and hemostasis optimized.^{12–18} In time, bloodless medicine and surgery (BMS) programs emerged.^{4,19,20} The key clinical “innovation” was combining different strategies and providing them in a coordinated peritreatment manner by a multidisciplinary team.^{4,21–23} By the mid-1990s, there were already over 100 hospital-based programs or centers reported to exist across the globe (with over half of them in the United States).^{24,25}

In time, all forms of complex surgery and medical conditions were being treated without resorting to blood transfusion. The outcomes were equivalent or better than matched patients with transfusion.^{26–37} This led clinicians involved in these programs to extend the principles to their total patient populations.

The fundamental idea that medical care with little or no allogeneic blood is a possibility and does not necessarily lead to death or disability opened many doors. At the same time, mounting evidence has shown that allogeneic transfusion is independently associated in a risk-adjusted, dose-dependent relationship with increased morbidity, mortality, and

hospital length of stay.^{38–55} There are also ongoing safety, health care cost, and supply challenges.^{13,14,56–61}

Thus there is a strong driving force and duty (given the precautionary principle in medicine) to avoid or reduce transfusion whenever possible.^{62,63} BMS programs provided the proof of concept that effective strategies can be used to reduce the dependency on allogeneic blood, even in acute severely anemic patients and in high blood loss procedures.^{64–68}

However, there was resistance to the term “bloodless medicine and surgery” and the more generic term “blood conservation” became popular to communicate broader application.¹⁰ Under the blood conservation concept, a patient’s own blood is considered a highly valuable and limited resource that must be “conserved and managed appropriately.”^{69,70} While the term “blood conservation” is still commonly used,⁷¹ the expanding list of modalities utilized (particularly those addressing the management of anemia and bleeding) go beyond the confinements of simple “conservation.” This expanded thinking made the case for the more inclusive term “blood management.”

Blood management appeared sporadically in the medical literature in the 1970s, primarily to refer to the supply management of blood from altruistic or paid donors. However, since then, it has reemerged as a concept related to the optimal management of the patient’s own blood. Accordingly, “patient” was added to the term to underscore the “patient-centered” versus “product-centered” approach,^{69,72} creating the term “patient blood management,” which is

increasingly in use today and seen as the new standard of care for all patients (Figure).^{72–75} The original concept of the term was to focus attention on good clinical management of the patient’s own blood, just like any other organ or organ system, and it was not about a specific intervention.

Good clinical medicine starts with a question (problem) not an answer (therapeutic management). For example, treating anemia alone without considering its mechanisms and underlying cause would not be expected to improve outcomes.^{76–79} Although transfusion can be an effective therapy for the acute management of life-threatening blood loss, efforts should be made to preemptively identify the risks of blood loss and implement preventive strategies to reduce this risk.⁸⁰ Accordingly, PBM is not an intervention per se: It is not about transfusion thresholds, appropriate transfusion, intravenous iron, or any other specific therapeutic intervention. Rather, it is the application of the principles of good clinical medicine, which include, first of all, diagnosis, followed by the consideration of appropriate patient-specific therapeutic options for management of that patient’s diagnosis, with patient engagement, shared decision-making, informed consent, and clinical follow-up. This overall approach is most likely to improve patient satisfaction and clinical outcome.

WHY PBM SHOULD NOT BE CENTERED ON TRANSFUSION

Beginning with a landmark randomized controlled trial (RCT) published in 1999,⁸¹ almost 70 clinical trials




Figure. Growth in the annual number of publications indexed in PubMed focusing on PBM and related disciplines. PBM indicates patient blood management.

have been conducted comparing liberal versus restrictive transfusion strategies in various patient populations.^{82–84} A 2020 overview of the evidence found that, in meta-analyses with high- to moderate-quality evidence, a restrictive transfusion strategy had a similar or superior outcome compared with a liberal transfusion strategy.⁸⁵

However, a focus on appropriate transfusion and transfusion strategies can result in a practice that forgets that PBM is much more than a single therapeutic option. It has been demonstrated that appropriate transfusions can often be avoidable with PBM.⁶³ It is important to note that transfusion is a therapy administered to acutely treat an anomaly without addressing the underlying etiology. Even in the context of acute surgical blood loss, blood transfusions are only a supportive therapy with limited effectiveness and established safety concerns in the absence of surgical control of the source of bleeding. PBM, however, is an integrated and comprehensive strategy to provide patient care that aims to assess and address the etiology of those anomalies, when possible, rather than promoting a short-term therapy (transfusion) without addressing the underlying cause.⁸⁶

Transfusion trials have been predominantly focused on comparing various transfusion thresholds, based on arbitrary Hb levels, without regard to the underlying etiology or the patient's tolerance to the low Hb level.^{86,87}

While PBM has incorporated the concept of restrictive transfusion strategy from these trials as a guide to determine when a transfusion may be clinically indicated, PBM offers far more for the medical and surgical management of patients.^{88–91}

Anemia has many causes, and it is often acquired or worsened during hospital stay.^{76,92} Good clinical practice dictates that the underlying problem and mechanisms should be identified, diagnosed and, where possible, managed and treated appropriately. Iron deficiency and iron deficiency anemia require iron therapy.^{93–96} Noniron deficiency anemia and anemia of inflammation require more nuanced management including identifying and addressing the underlying cause.^{97–99} Here, an inflammatory response leads to an iron problem, an erythropoietin problem, a hemolysis problem, and possibly a hematinic problem. Accordingly, therapeutic options include intravenous iron, erythropoietin, and where appropriate, hematinics.^{100,101}

Blood loss and bleeding are independently associated with adverse patient outcomes and have several possible causes.^{13,76,102–104} Blood loss can result from surgical and medical interventions, laboratory blood draws, and bleeding due to coagulopathy. There are multiple logistical, surgical, anesthetic, pharmacological, and coagulation management

(ie, the balance between clotting to death and bleeding to death)¹⁰⁵ strategies/therapies to minimize these blood losses as part of good clinical management and preservation of the patient's blood which improve patient outcomes.^{17,106,107} When clinically indicated, and with the informed consent of the patient, the use of allogeneic blood components may also be considered an option.¹⁰⁸

There are some 100 measures¹⁰⁹ making up this approach. They can be grouped under the problem-based “ABC Toolbox of PBM”—anemia, blood loss, and coagulation (Table 1).¹¹⁰

PAST AND PRESENT DEFINITIONS OF PBM: THEIR STRENGTHS AND WEAKNESSES

Simply stated, the end point of PBM is patient-centered, rather than blood product-centered, to achieve improved clinical outcomes and higher quality of care by consistently applying principles of patient safety.^{111,112} The reduction or avoidance of transfusion can be viewed as a secondary or corollary effect of PBM and a surrogate measure of its effectiveness.¹⁷

The definition and application of PBM is a dynamic process and continues to evolve (Table 2).^{17,113–120} One of the first formal definitions was put forward by SABM in 2007 and revised by SABM in 2012 to lessen the emphasis on the use of a product (blood), instead focusing on the patient or disease process by underscoring the key preemptive management strategies utilized under PBM. SABM currently defines PBM as “the timely application of evidence-based medical and surgical concepts designed to maintain Hb concentration, optimize hemostasis, and minimize blood loss in an effort to improve patient outcome.”¹¹³ A similar concept is captured in a consensus-developed definition used by the world's first health-system-wide PBM program in Western Australia and by IFPBM, “an evidence-based bundle of care that optimizes medical and surgical patient outcomes by clinically managing and preserving a patient's blood.”^{17,114} The SABM and WAPBM/IFPBM definitions have several elements in common. They do not include any specific intervention or modality, they are patient-focused, they include both medical and surgical patients, and the fundamental aim is to improve patient outcomes. Another deliberate key element is they include “evidence-based.” As described earlier, the definition of evidence-based medicine includes “patient values and preferences.” Patient engagement, shared decision-making, and informed consent are key components of modern health care. However, this important element of the definition is probably too subtle in these 2 definitions and is lost on many, as the common misconception is that evidence-based medicine refers to practice based on the latest evidence from clinical

Table 1. The ABC Toolbox for PBM

Tools	Anemia and iron deficiency	Blood loss and bleeding	Coagulopathy
1. Program implementation methodology	<ul style="list-style-type: none"> • Change culture across your institution • Disseminate evidence-based PBM guidelines/recommendations and detect and discourage nonevidence-based practices • Translate evidence-based guidelines/recommendations into clinical practice • Identify practice areas that need improvement 		
2. Diagnostic devices	<ul style="list-style-type: none"> • Point-of-care hemoglobin analyzers • Point-of-care testing for iron deficiency if available 	<ul style="list-style-type: none"> • Point-of-care coagulation and platelet function testing and goal-directed treatment • Rapid diagnostic tests for the presence of DOACs if available 	<ul style="list-style-type: none"> • Point-of-care coagulation and platelet function testing and goal-directed treatment • Rapid diagnostic tests for presence of DOACs if available
3. Treatment devices		<ul style="list-style-type: none"> • Pre- and postoperative cell recovery (cell saver) • ANH 	
4. Pharmaceuticals	<ul style="list-style-type: none"> • Oral/intravenous iron • Folic acid • Vitamin B12 • Erythropoiesis-stimulating agents • Educate physicians on indications and dosage 	<ul style="list-style-type: none"> • Antifibrinolytics (tranexamic acid, aminocaproic acid) • Topical hemostatic agents • Local vasoconstrictive agents • WBC and platelet-stimulating agents where appropriate • Consider high FiO_2 (1.0) in patients with life-threatening anemia 	<ul style="list-style-type: none"> • Fibrinogen concentrate • PCC • Other clotting factors • Vitamin K intravenously
5. Vigilance with nutritional and pharmacological interactions	<p>Identify and manage drug therapies and/or nutrition that:</p> <ul style="list-style-type: none"> • Can contribute to anemia and hematinic deficiencies (eg, PPIs) • Can increase iron absorption (eg, ascorbic acid) • Can impair absorption (eg, some vitamin and herbal supplements, tea, coffee, or dairy products) 	<p>Identify and manage drug therapies and/or nutrition that increase the bleeding risk, for example:</p> <ul style="list-style-type: none"> • NSAIDs (including COX2 inhibitors), antidepressants, statins, antiarrhythmics • Vitamin and herbal supplements including vitamin E, vitamin K, garlic, ginger, Ginkgo biloba, fish oil, chamomile, dandelion root, etc 	
6. General principles	<p>Identify, evaluate, and manage anemia and iron deficiency:</p> <ul style="list-style-type: none"> • Evaluate and manage underlying disorders causing anemia and iron deficiency • Be aware of drugs associated with red blood cell disorders • Anemia management program for prehospital, hospital, and postdischarge patients • Focus on patients with comorbidities (diabetes, chronic kidney disease, and congestive heart failure) 	<ul style="list-style-type: none"> • Meticulous surgical hemostasis • Optimize surgical technique • Patient positioning • Efforts to stop bleeding immediately Minimally invasive surgical techniques Restrictive fluid administration and permissive hypotension until bleeding is controlled Achieving euvolemia once bleeding controlled Deliberate induced hypotension Careful blood pressure and fluid management Prevent hypothermia, hypoperfusion, and acidosis Maintaining normal circulating volume (euvolemia) • Minimize iatrogenic blood loss, minimize number of blood draws and volume, minimize volume of blood wasted (microtainers/small phlebotomy tubes) • Staging and packing • Interventional radiologic embolization • Restrictive transfusion strategy (reduce volume of transfusion, adhere to restrictive transfusion thresholds) • Watch for signs of postoperative bleeding • Monitor throughout withholding/bridging/recommencement of DOACs and antiplatelet agents • Prevent GI bleeding (enteral feeding/food, GI acid-lowering agents) • Avoid/treat infections promptly 	<ul style="list-style-type: none"> • Address clinically significant coagulopathy early by identifying the source and/or coagulation defect
	<ul style="list-style-type: none"> • Identify patients and surgical procedures at increased risk for blood loss, anemia, and coagulopathy • Refer high-risk patients immediately to PBM program • Preoperative surgical planning to minimize extent and the time of surgery including preoperative embolization or noninvasive techniques • Postpone or cancel elective surgery to allow time to optimize blood health 		

(Continued)

Table 1. Continued

Tools	Anemia and iron deficiency	Blood loss and bleeding	Coagulopathy
7. SOP and procedural guidelines	<ul style="list-style-type: none"> SOPs for detection, evaluation, and management of anemia and iron deficiency for specific settings: Pre- and postsurgery Cancer Heart failure Chronic kidney disease Pregnancy and postpartum Pediatrics Hospital-acquired anemia Patients with iron-restricted erythropoiesis Anemia of inflammation 	<ul style="list-style-type: none"> Management of anticoagulants and antiplatelet agents before interventions Bleeding history-taking Bleeding management algorithms Procedural guideline for cell salvage Procedural guideline for ANH Maintaining normothermia Major hemorrhage protocol Guidelines on oral versus intravenous iron, iron preparations, and dosing Establish “single-unit transfusion policy” 	
8. Data collection, benchmarking, and reporting systems	<ul style="list-style-type: none"> Patient-centered and data-driven decision-making Measure the change with respect to patient outcomes/cost savings Report the change 		
9. Continuous education and training	<ul style="list-style-type: none"> Multidisciplinary and multiprofessional programs organized and led by local champions Regular updating of curricula/learning content Ensuring introductory courses for new and junior staff 		
10. Patient education, information, and consent	<ul style="list-style-type: none"> Develop a simplified education management plan Establish procedures for communicating with patients retreatment plan, risks/benefits, and obtaining consent Communicate plan to all members of the team 		
11. Infrastructure	<ul style="list-style-type: none"> Appoint PBM staff and allocate/reallocate funds accordingly Create job descriptions for PBM-dedicated staff Re-engineer clinical pathways and infrastructure to allow appropriate preoperative/preintervention patient assessment and optimization Ensure appropriate waiting zones and treatment areas particularly for preoperative/preintervention patient optimization Form a multidisciplinary PBM committee 	<ul style="list-style-type: none"> Install necessary medical devices and equipment 	

From the IFPBM-SABM Workgroup; Shander et al.²⁶

Abbreviations: ABC, Anemia, Blood loss and Coagulopathy; ANH, acute normovolemic hemodilution; COX2, cyclooxygenase-2; DOACs, direct oral anticoagulants; FiO₂, fraction of inspired oxygen; GI, gastrointestinal; IFPBM-SABM, International Foundation for Patient Blood Management-Society for the Advancement of Blood Management; NSAID, nonsteroidal anti-inflammatory drug; PBM, patient blood management; PCC, prothrombin complex concentrate; PPI, proton-pump inhibitor; SOP, standard operating procedure; WBC, white blood cell.

trials. Accordingly, this is a deficiency with these 2 definitions of PBM.

The strength of the WAPBM definition is that it highlights a bundle of care, not a bundle of interventions. Many of the strategies of PBM relate to evaluation, diagnosis, and monitoring. However, the term bundle of care is commonly seen as being quite prescriptive, confined to a small straightforward set of practices. PBM is broader and more nuanced. The SABM definition seeks to define the framework of care by including the important concept that PBM is a multiprofessional team approach. An important element in the WAPBM/IFPBM definition is “clinically managing and preserving a patient’s blood.” Clinically speaking, management has always included diagnosis, treatment, and follow-up⁷⁸ which are key components of the PBM concept.

Other definitions have emerged (Table 2) that variously include some of the elements of these 2 definitions. Some add the concept of a “multidisciplinary approach,” a key element of PBM. However, several definitions retain a single intervention or product focus, which is not consistent with the concept of PBM. Additionally, definitions that include limiting terms

such as “patients who might need blood” excludes many other patients who would benefit from PBM modalities, not only those about to undergo an invasive procedure with high risk for transfusion. For example, an estimated 2.4 billion people across the globe are anemic.¹²¹ Of these, it is estimated that 1.2 billion have iron deficiency anemia.^{100,121–123} While difficult to determine, it is suggested that those suffering from iron deficiency without anemia could be at least double those with iron deficiency anemia.¹²⁴ If correct, it may mean that up to 2.4 billion people globally suffer the debilitating effects of iron deficiency and iron deficiency anemia. Many of these patients are probably not “in need of a transfusion” but they are definitely in need of PBM. Iron deficiency and iron deficiency anemia are major issues in women’s health, including in relation to heavy menstrual bleeding and pregnancy.¹²⁵ No country is on target to meet the World Health Organization (WHO) global target of a 50% reduction in the percentage of women with anemia by 2025.¹²⁶ This is an unmet need that PBM can address.

A product-focused definition also excludes patients in low-income countries where blood is simply not available or, if it is, has a high risk of

Table 2. Current Definitions of Patient Blood Management^{24,96–103}

Organization	Definition	Date first published
SABM (early) ⁹⁶	“Appropriate provision and use of blood, its components and derivatives, and strategies to reduce or avoid the need for a blood transfusion, with the ultimate goal of improved patient outcome”	2007
SABM (current) ⁹⁶	“The timely application of evidence-based medical and surgical concepts designed to maintain Hb concentration, optimize hemostasis, and minimize blood loss in an effort to improve patient outcome”	2012
Western Australia PBM Group ²⁴	“An evidence-based bundle of care that optimizes medical and surgical patient outcomes by clinically managing and preserving a patient’s own blood”	2016
IFPBM ⁹⁷	“An evidence-based bundle of care that optimizes medical and surgical patient outcomes by clinically managing and preserving a patient’s own blood”	2016
WHO ⁹⁸	“A set of evidence-based practices to optimize medical and surgical patient outcomes through preservation of the patient’s own blood”	2020
AABB ⁹⁹	“An evidence-based, multidisciplinary approach to optimizing the care of patients who might need transfusion. PBM encompasses all aspects of patient evaluation and clinical management surrounding the transfusion decision-making process, including the application of appropriate indications, as well as minimization of blood loss and optimization of patient red cell mass. PBM can reduce the need for allogeneic blood transfusions and reduce health care costs, while ensuring that blood components are available for the patients who need them”	2021
Joint UK Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee ¹⁰⁰	“A multidisciplinary, evidence-based approach to optimising the care of patients who might need a blood transfusion. PBM puts the patient at the heart of decisions made about blood transfusion to ensure they receive the best treatment and avoidable, inappropriate use of blood and blood components is reduced”	2021
National Blood Authority (Australia) ^{101,102}	“PBM aims to improve clinical outcomes by avoiding unnecessary exposure to blood components. It includes the three pillars: optimisation of blood volume and red cell mass; minimisation of blood loss; and optimisation of the patient’s tolerance of anaemia”	2021
Australia Commission on Safety and Quality in Health Care ¹⁰³	“PBM takes an individualised, multidisciplinary approach to the management of a patient’s blood, through assessment and the development of a management plan to: Optimise a patient’s own blood (identify and address the health conditions that might lead to a blood transfusion such as anaemia or iron deficiency); minimise blood loss (such as surgical techniques that reduce blood loss); and optimise tolerance of anaemia (with appropriate management, the body may tolerate anaemia without resorting to blood transfusion”	2021

Abbreviations: AABB, Association for the Advancement of Blood & Biotherapies; IFPBM, International Foundation for Patient Blood Management; PBM, patient blood management; SABM, Society for the Advancement of Blood Management; WHO, World Health Organization.

transfusion-transmitted disease. As such, a definition that is tied to a single intervention (such as transfusion, or to those who may be in need of transfusion) cannot accurately represent the globally applicable PBM practice framework.

Nor is PBM narrowly confined to putting “the patient at the heart of transfusion decisions” as suggested by one definition (Table 2). Such a definition confines PBM to a single intervention and reduces it to an “appropriate transfusion”-based concept.

Finally, almost all current definitions fail to include the key element of patient empowerment and informed consent. It is included in the description of PBM in the Australian Patient Blood Management Guidelines, but is not part of a formal definition of PBM and can easily be overlooked. Given the wide variety of definitions proffered, and the strengths and weaknesses of all, a clear, all-encompassing definition that captures the true concept of patient-focused PBM is needed. Such a definition is likely to contribute to improved clinical practice and patient outcomes as demonstrated by PBM programs based on these multidisciplinary multimodal concepts.^{17,127}

PROPOSED KEY CONCEPTS TO BE INCLUDED IN A GLOBAL DEFINITION OF PBM

- A patient-centered approach. First and foremost, PBM aims to improve patient outcomes while adhering to the principles of patient safety and good clinical medicine. All efforts made by all personnel are centered on the patient and not on the process. The patient is given the power to intervene. Patient values, preferences, and choices are central to the process. Accordingly, informed consent is also central to PBM. To quote Sir William Osler, “The good physician treats the disease, the great physician treats the patient who has the disease.”
- A comprehensive approach to anemia and blood homeostasis. This includes the diagnosis and management of all patients with anemia of any cause (eg, iron deficiency, acute and chronic inflammation) as well as deficiencies of other components of the patient’s blood, minimization of blood losses and preserving the patient’s own blood before (eg, cessation of anticoagulant or antiplatelet therapy, correction

of a coagulopathy), during (eg, blood-sparing techniques and drugs, correction of a coagulopathy), and after (eg, blood-sparing techniques and drugs, correction of a coagulopathy) any treatment, and the optimal management of post-treatment anemia (optimizing the patient's and provider's tolerance of anemia, correcting anemia when required, minimizing iatrogenic losses, etc). It includes application of these principles to the health and wellness of the general population even when no hospital admission is contemplated.

- An evidence-based approach. This approach emphasizes the integration of the best available research evidence with clinical expertise and patient values and preferences.⁵
- A multidisciplinary approach. PBM is an integrated, institutional (hospital or other health care setting) approach to blood homeostasis. Physicians, nurses, perfusionists, respiratory therapists, pharmacists, administrators, governments, etc, are all involved in the implementation of PBM.
- A preventive approach. PBM underscores the importance of giving precedence to prevention over treatment whenever possible (eg, preventive measures for anemia, coagulopathy, blood losses).
- A focus on patient outcomes rather than choice of treatments. Finally, focus on a default treatment modality/option such as transfusion or any other single intervention should be precluded from a global definition of PBM. Treatment modalities are only intermediate variables that will vary in different settings and with time, while improved patient outcomes (quality of life and reduced morbidity and mortality) are the essence of PBM.¹²⁸

THE PROPOSED GLOBAL DEFINITION OF PBM

In view of the above, the Global Definition of PBM as endorsed by NATA, SABM, IFPBM, WAPBM, the American Society of Anesthesiologists' (ASA) Committee on PBM, the Asia-Pacific Society for Patient Blood Management (ASPB), the Chinese Society for Patient Blood Management (CSPBM), the Korean Society for Patient Blood Management (KPBM), the Korean Society of Anesthesiologists (KSA), the Malaysian Society of Haematology (MSH), the Canadian Ontario Nurse Transfusion Coordinator (ONTraC) Program, the South African National Blood Service (SANBS), National Association of Patient Blood Management Specialists Russia Federation (NAS PBM), the American Society of Extracorporeal Technology (AmSECT), the Anemia Working Group Spain (AWGE), and the Society of Cardiovascular Anesthesiologists (SCA) reads as follows:

Patient blood management is a patient-centered, systematic, evidence-based approach to improve patient outcomes by managing and preserving a patient's own blood, while promoting patient safety and empowerment.

A glossary of the terms used in the definition is provided in Table 3. The definition emphasizes the critical role of informed choice. PBM involves the timely, multidisciplinary application of evidence-based medical and surgical concepts aimed at (1) screening for, diagnosing and appropriately treating anemia, (2) minimizing surgical, procedural, and laboratory sampling blood losses and managing coagulopathic bleeding throughout the care episode, and (3) supporting the patient while appropriate treatment is initiated. We believe the proposed definition captures all these concepts and more with comprehensive brevity.

Table 3. Glossary of Terms and Definitions

Term	Definition
Patient	Includes both surgical and medical patients
Blood management	An extensive list of options and measures for PBM should be considered and employed to proactively manage and preserve the patient's own blood
Patient-centered	Providing care that is respectful of and responsive to individual patient preferences, needs, and values, and ensuring that patient values guide all clinical decisions
Systematic	An organized uniform approach should be employed acting methodically according to an organized multidisciplinary team plan or system
Evidence-based	The integration of the best available research evidence with clinical expertise and patient values and preferences
Outcomes	The desired patient-centered outcomes, for example, decreased morbidity and mortality, shorter length-of-stay, should be clearly delineated
Managing	Includes diagnosis, treatment, and follow-up. Diagnose any blood failures such as anemia, deficiencies, coagulopathies, thrombocytopenia, etc; treat/correct, where possible, underlying conditions and deficiencies, monitor and follow-up
Preserving the patient's own blood	All appropriate measures to preserve the patient's blood should be applied, including surgical, procedural, iatrogenic, and coagulopathic blood losses and patient-specific tolerance of anemia when consistent with patient safety
Safety	The patient's safety, including avoidance of preventable harm, and benefit/risk calculation should be paramount
Patient empowerment	Patients should be preemptively informed of their diagnosis, prognosis, treatment options, and alternatives, including benefits and risks of receiving or declining therapies; they should actively participate in decision-making and informed consent should be obtained and documented

Abbreviation: PBM, patient blood management.

Emanating from this medically oriented, comprehensive definition, we further propose a shorter version for use by laypersons:

Patient blood management is a patient-centered and organized approach in which the entire health care team coordinates efforts to improve results by managing and preserving a patient's own blood.

Patient values, preferences, and choices are central to the process. PBM involves the application of the best therapies (and at times, withholding unwarranted interventions) to manage and preserve a patient's own blood through the timely management of anemia and the prevention or control of any source of blood loss.

CONCLUSIONS

The expansion of PBM worldwide has been gaining momentum over the past few years. With the current ongoing pandemic, it is likely that the role of PBM will become even more important given the heightened attention on the potential risks of transfusion and possible constraints on blood supply. PBM is endorsed by the WHO and PBM strategies are being implemented in many countries around the globe. This is why IFPBM, NATA, SABM, WAPBM, ASA, ASPBM, CSPBM, KPBM, KSA, MSH, ONTraC, SANBS, NAS PBM, AmSECT, AWGE, and SCA have formed the "Global Definition Group."

We believe that having a common definition for PBM will assist all those involved (PBM organizations, hospital administrators, individual clinicians including primary care physicians, etc) focus on the appropriate issues when discussing, teaching, and implementing PBM, thereby contributing to improved patient care and outcomes. The definition emphasizes a patient-centered, global, evidence-based, multidisciplinary, and interprofessional approach. Prevention must be given precedence over treatment whenever possible, and emphasis on a single treatment modality such as transfusion is not part of the definition. The definition will evolve with time as science, medical practice, and patient preoccupations, priorities, and preferences evolve. Accordingly, those involved in the preparation of this definition call upon all stakeholders including other PBM organizations to join them and reconvene to review and revise the definition over the coming years. ■■

DISCLOSURES

Name: Aryeh Shander, MD.

Contribution: This author helped in developing the initial draft, discussing the initial draft, and approving the proposed definition; revised the manuscript; and approved the final submission.

Conflicts of Interest: A. Shander has received research grants from CSL Behring, Gauss Surgical, Masimo,

and HbO2 Therapeutics, honoraria from CSL Behring, Masimo, and Merck and acted as a consultant for CSL Behring, Gauss Surgical, Masimo Corporation, and Vifor.

Name: Jean-Francois Hardy, MD.

Contribution: This author helped in developing the initial draft, discussing the initial draft, and approving the proposed definition; revised the manuscript; and approved the final submission.

Conflicts of Interest: J.-F. Hardy has received honoraria from Pfizer Canada and Nordic Pharma.

Name: Sherri Ozawa, RN.

Contribution: This author helped in developing the initial draft, discussing the initial draft, and approving the proposed definition; revised the manuscript; and approved the final submission.

Conflicts of Interest: S. Ozawa is a founding member of SABM and a member of the Board of Directors.

Name: Shannon L. Farmer, DHSc.

Contribution: This author helped in discussing the initial draft and approving the proposed definition, revised the manuscript, and approved the final submission.

Conflicts of Interest: S. L. Farmer has received personal fees from Thieme and Elsevier Science USA and non-financial support from the National Blood Authority (Australia), the Medical Society for Blood Management, and The Health Round Table.

Name: Axel Hofmann, Dr.rer.med.

Contribution: This author helped in discussing the initial draft and approving the proposed definition, revised the manuscript, and approved the final submission.

Conflicts of Interest: A. Hofmann has received personal fees from Vifor Pharma AG and TEM International GmbH.

Name: Steven M. Frank, MD.

Contribution: This author helped in reviewing and discussing the revised manuscript and approved the final submission.

Conflicts of Interest: S. M. Frank has been on scientific advisory boards for Haemonetics, Medtronic, and Baxter.

Name: Daryl J. Kor, MD.

Contribution: This author helped in reviewing and discussing the revised manuscript and approved the final submission.

Conflicts of Interest: D. J. Kor has been on the Scientific Advisory Board with Terumo Medical Corporation, Consultant with Instrumentation Laboratory, UpToDate, Consultant at the National Institutes of Health (NIH), and received grant funding from NIH.

Name: David Faraoni, MD.

Contribution: This author helped in approval of the final draft of the definition and the manuscript, participated in the final editing, contributed revisions to the manuscript, and approved the final submission.

Conflicts of Interest: None.

Name: John Freedman, MD.

Contribution: This author helped in developing the initial draft, contributed to the concept of the definition, helped in multiple revisions of the manuscript, and approved the final submission.

Conflicts of Interest: None.

This manuscript was handled by: Susan Goobie, MD, FRCPC.

REFERENCES

- Luther E. Post-partum haemorrhage: its treatment, antipatory and actual. Paper presented at: Transactions of the Intercolonial Medical Congress 1899; Brisbane, Australia. September 19, 1988. <https://archive.org/details/b28083593/page/32/mode/2up>.
- Watson A. The saving of blood in gynaecological operations. Paper presented at: Transactions of the 5th session of the Intercolonial Medical Congress 1899; Brisbane, Australia. September 19, 1988. <https://archive.org/details/b28083593/page/32/mode/2up>.
- Amin M, Wilson K, Tinmouth A, Hébert P. Does a perception of increased blood safety mean increased blood transfusion? An assessment of the risk compensation theory in Canada. *BMC Public Health*. 2004;4:20.
- Martyn V, Farmer SL, Wren MN, et al. The theory and practice of bloodless surgery. *Transfus Apher Sci*. 2002;27:29–43.
- Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. *Vox Sang*. 2002;83(suppl 1):383–386.
- Cooley DA. Conservation of blood during cardiovascular surgery. *Am J Surg*. 1995;170(suppl 6A):53S–59S.
- Isbister J. The three-pillar matrix of patient blood management. *ISBT Sci Series*. 2015;10(suppl 1):286–294.
- Ott DA, Cooley DA. Cardiovascular surgery in Jehovah's Witnesses. Report of 542 operations without blood transfusion. *JAMA*. 1977;238:1256–1258.
- Zaorski JR, Hallman GL, Cooley DA. Open heart surgery for acquired heart disease in Jehovah's Witnesses. A report of 42 operations. *Am J Cardiol*. 1972;29:186–189.
- Uitley JR, Moores WY, Stephens DB. Blood conservation techniques. *Ann Thorac Surg*. 1981;31:482–490.
- Stager WR. Blood conservation by autotransfusion. *AMA Arch Surg*. 1951;63:78–82.
- Goodnough LT, Shander A. Patient blood management. *Anesthesiology*. 2012;116:1367–1376.
- Farmer SL, Towler SC, Leahy MF, Hofmann A. Drivers for change: Western Australia Patient Blood Management Program (WA PBMP), World Health Assembly (WHA) and Advisory Committee on Blood Safety and Availability (ACBSA). *Best Pract Res Clin Anaesthesiol*. 2013;27:43–58.
- Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. *Oncologist*. 2011;16(suppl 3):3–11.
- Hofmann A, Farmer S, Towler SC. Strategies to preempt and reduce the use of blood products: an Australian perspective. *Curr Opin Anaesthesiol*. 2012;25:66–73.
- Shander A, Isbister J, Gombotz H. Patient blood management: the global view. *Transfusion*. 2016;56(suppl 1):S94–S102.
- Leahy MF, Hofmann A, Towler S, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. *Transfusion*. 2017;57:1347–1358.
- Madjdpour C, Spahn DR, Weiskopf RB. Anemia and perioperative red blood cell transfusion: a matter of tolerance. *Crit Care Med*. 2006;34:S102–S108.
- Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. *Curr Opin Hematol*. 2006;13:462–470.
- Shander A. Surgery without blood. *Crit Care Med*. 2003;31(suppl 12):S708–S714.
- Helm RE, Rosengart TK, Gomez M, et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. *Ann Thorac Surg*. 1998;65:125–136.
- Rosengart TK, Helm RE, DeBois WJ, Garcia N, Krieger KH, Isom OW. Open heart operations without transfusion using a multimodality blood conservation strategy in 50 Jehovah's Witness patients: implications for a "bloodless" surgical technique. *J Am Coll Surg*. 1997;184:618–629.
- Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. *Transfusion*. 2003;43:668–676.
- Farmer SL, Webb D. *Your Body, Your Choice*. Media Masters; 2000.
- Robb N. Jehovah's Witnesses leading education drive as hospitals adjust to no blood requests. *CMAJ*. 1996;154:557–560.
- Chigbu B, Onwere S, Kamanu C, et al. Lessons learned from the outcome of bloodless emergency laparotomies on Jehovah's Witness women presenting in the extremis with ruptured uterus. *Arch Gynecol Obstet*. 2009;279:469–472.
- Sharma P, Barajas FJ, Krishnamoorthy P, Campo LM, Blumenthal E, Spinnell M. Transfusion-free management of gastrointestinal bleeding: the experience of a bloodless institute. *J Clin Gastroenterol*. 2015;49:206–211.
- Varela JE, Gomez-Marin O, Fleming LE, Cohn SM. The risk of death for Jehovah's Witnesses after major trauma. *J Trauma*. 2003;54:967–972.
- Whitson BA, Huddleston SJ, Savik K, Shumway SJ. Bloodless cardiac surgery is associated with decreased morbidity and mortality. *J Card Surg*. 2007;22:373–378.
- Jabbour N, Gagandeep S, Mateo R, Sher L, Genyk Y, Selby R. Transfusion free surgery: single institution experience of 27 consecutive liver transplants in Jehovah's Witnesses. *J Am Coll Surg*. 2005;201:412–417.
- Jabbour N, Gagandeep S, Thomas D, et al. Transfusion-free techniques in pediatric live donor liver transplantation. *J Pediatr Gastroenterol Nutr*. 2005;40:521–523.
- Fernandes CJ, Hagan R, Frieberg A, Grauaug A, Kohan R. Erythropoietin in very preterm infants. *J Paediatr Child Health*. 1994;30:356–359.
- Burnett CM, Duncan JM, Vega JD, Lonquist JL, Sweeney MS, Frazier OH. Heart transplantation in Jehovah's Witnesses. An initial experience and follow-up. *Arch Surg*. 1990;125:1430–1433.
- Chan EG, Morrell MR, Chan PG, Sanchez PG. Bilateral sequential lung transplantation in Jehovah's Witnesses. *Perfusion*. 2020;36:672–676.
- Brown NM, Matthews B, Ford PA. Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol. *Commun Oncol*. 2006;3:776–781.
- Kaufman DB, Sutherland DE, Fryd DS, Ascher NL, Simmons RL, Najarian JS. A single-center experience of renal transplantation in thirteen Jehovah's Witnesses. *Transplantation*. 1988;45:1045–1049.
- Goldaracena N, Méndez P, Quiñonez E, et al. Liver transplantation without perioperative transfusions single-center experience showing better early outcome and shorter hospital stay. *J Transplant*. 2013;2013:649209.
- Shander A, Javidrooz M, Ozawa S, Hare GM. What is really dangerous: anaemia or transfusion? *Br J Anaesth*. 2011;107(suppl 1):i41–i59.
- Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A. Adverse blood transfusion outcomes: establishing causation. *Transfus Med Rev*. 2011;25:89–101.
- Patel SV, Kidane B, Klingel M, Parry N. Risks associated with red blood cell transfusion in the trauma population, a meta-analysis. *Injury*. 2014;45:1522–1533.
- Ejaz A, Frank SM, Spolverato G, Kim Y, Pawlik TM. Defining transfusion triggers and utilization of fresh frozen plasma and platelets among patients undergoing

- hepatopancreaticobiliary and colorectal surgery. *Ann Surg.* 2015;262:1079–1085.
42. Smith MM, Kor DJ, Frank RD, Weister TJ, Dearani JA, Warner MA. Intraoperative plasma transfusion volumes and outcomes in cardiac surgery. *J Cardiothorac Vasc Anesth.* 2020;34:1446–1456.
43. Murad MH, Stubbs JR, Gandhi MJ, et al. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. *Transfusion.* 2010;50:1370–1383.
44. Newland A, Bentley R, Jakubowska A, et al. A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. *Hematology.* 2019;24:679–719.
45. Thorn S, Güting H, Mathes T, Schäfer N, Maegele M. The effect of platelet transfusion in patients with traumatic brain injury and concomitant antiplatelet use: a systematic review and meta-analysis. *Transfusion.* 2019;59:3536–3544.
46. Trentino KM, Leahy MF, Sanfilippo FM, et al. Associations of nadir haemoglobin level and red blood cell transfusion with mortality and length of stay in surgical specialties: a retrospective cohort study. *Anaesthesia.* 2019;74:726–734.
47. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. *JAMA.* 2014;311:1317–1326.
48. Goobie SM, Faraoni D, Zurakowski D, DiNardo JA. Association of preoperative anemia with postoperative mortality in neonates. *JAMA Pediatr.* 2016;170:855–862.
49. Goobie SM, DiNardo JA, Faraoni D. Relationship between transfusion volume and outcomes in children undergoing noncardiac surgery. *Transfusion.* 2016;56:2487–2494.
50. Whitlock EL, Kim H, Auerbach AD. Harms associated with single unit perioperative transfusion: retrospective population based analysis. *BMJ.* 2015;350:h3037.
51. Hopewell S, Omar O, Hyde C, Yu LM, Doree C, Murphy MF. A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010. *BMJ Open.* 2013;3:e002154.
52. Patient Blood Management Guidelines: Module 2 Perioperative. National Blood Authority: Canberra, ACT, Australia. 2012. Accessed December 2021. <https://www.blood.gov.au/pbm-module-2>.
53. Paone G, Likosky DS, Brewer R, et al. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. *Ann Thorac Surg.* 2014;97:87–93.
54. Paone G, Brewer R, Theurer PF, Bell GF, Cogan CM, Prager RL. Preoperative predicted risk does not fully explain the association between red blood cell transfusion and mortality in coronary artery bypass grafting. *J Thorac Cardiovasc Surg.* 2012;143:178–185.
55. Ferraris VA, Davenport DL, Saha SP, Austin PC, Zwischenberger JB. Surgical outcomes and transfusion of minimal amounts of blood in the operating room. *Arch Surg.* 2012;147:49–55.
56. Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. *ISBT Sci Ser.* 2014;9:30–36.
57. Bolcato M, Russo M, Trentino K, Isbister J, Rodriguez D, Aprile A. Patient blood management: the best approach to transfusion medicine risk management. *Transfus Apher Sci.* 2020;59:102779.
58. Trentino KM, Farmer SL, Swain SG, et al. Increased hospital costs associated with red blood cell transfusion. *Transfusion.* 2015;55:1082–1089.
59. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. *Transfusion.* 2010;50:753–765.
60. Shander A, Ozawa S, Hofmann A. Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital. *Vox Sang.* 2016;111:55–61.
61. Hofmann A, Ozawa S, Shander A. Activity-based cost of platelet transfusions in medical and surgical inpatients at a US hospital. *Vox Sang.* 2021;116:998–1004.
62. Goobie SM. A blood transfusion can save a child's life or threaten it. *Paediatr. Anaesth.* 2015;25:1182–1183.
63. Trentino KM, Mace HS, Leahy MF, Sanfilippo FM, Farmer SL, Murray K. Appropriate red cell transfusions are often avoidable through patient blood management. *Blood Transfus.* 2020;19:177–178.
64. Shander A, Javidroozi M, Gianatiempo C, et al. Outcomes of protocol-driven care of critically ill severely anemic patients for whom blood transfusion is not an option. *Crit Care Med.* 2016;44:1109–1115.
65. Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. *Arch Intern Med.* 2012;172:1154–1160.
66. Frank SM, Wick EC, Dezern AE, et al. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. *Transfusion.* 2014;54(10 pt 2):2668–2677.
67. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. *Transfusion.* 1994;34:396–401.
68. Usoro NI, Emechebe CI, Okonkwo CU, et al. Bloodless management of severe obstetric hemorrhage with very severe anemia: a case report. *A A Pract.* 2021;15:e01396.
69. Isbister JP. Clinicians as gatekeepers: what is the best route to optimal blood use? *Dev Biol (Basel).* 2007;127:9–14.
70. Shander A, Moskowitz DM, Javidroozi M. Blood conservation in practice: an overview. *Br J Hosp Med (Lond).* 2009;70:16–21.
71. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. *Ann Thorac Surg.* 2011;91:944–982.
72. Farmer SL, Isbister JP, Leahy MF. History of transfusion and patient blood management. In: Jabbour N, ed. *Transfusion Free Medicine and Surgery*. 2nd ed. Wiley-Blackwell; 2014.
73. Thomson A, Farmer S, Hofmann A, Isbister J, Shander A. Patient blood management—a new paradigm for transfusion medicine? *ISBT Sci Ser.* 2009;4:423–435.
74. Spahn DR, Moch H, Hofmann A, Isbister JP. Patient blood management: the pragmatic solution for the problems with blood transfusions. *Anesthesiology.* 2008;109:951–953.
75. Spahn DR. Patient blood management: the new standard. *Transfusion.* 2017;57:1325–1327.
76. Krishnasivam D, Trentino KM, Burrows S, et al. Anemia in hospitalized patients: an overlooked risk in medical care. *Transfusion.* 2018;58:2522–2528.
77. Hardy JF, Farmer SL, Auerbach M, et al. Preoperative intravenous iron in anemic patients undergoing major abdominal surgery may not PREVENTT blood transfusions but still contribute to the objectives of patient blood management. *Anesth Analg.* 2021;132:1174–1177.
78. Isbister J. Investigating and treating anaemia. *Curr Ther.* 2000;October:39–48.
79. Isbister JP. Clinching the diagnosis: what would Osler say today? *Pathology.* 1983;15:36L–363.
80. Patient Blood Management Guidelines: Module 1 Critical Bleeding/Massive Transfusion. National Blood Authority (Australia). 2011. Accessed May 21, 2020. <https://www.blood.gov.au/pbm-module-1>

81. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med*. 1999;340:409–417.
82. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev*. 2016;10:CD002042.
83. Carson JL, Stanworth SJ, Alexander JH, et al. Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease. *Am Heart J*. 2018;200:96–101.
84. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. *JAMA*. 2021;325:552–560.
85. Trentino KM, Farmer SL, Leahy MF, et al. Systematic reviews and meta-analyses comparing mortality in restrictive and liberal haemoglobin thresholds for red cell transfusion: an overview of systematic reviews. *BMC Med*. 2020;18:154.
86. Shander A, Kim TY, Goodnough LT. Thresholds, triggers or requirements-time to look beyond the transfusion trials. *J Thorac Dis*. 2018;10:1152–1157.
87. Trentino KM, Farmer SL, Isbister JP, et al. Restrictive versus liberal transfusion trials: are they asking the right question? *Anesth Analg*. 2020;131:1950–1955.
88. Spahn DR, Schoenrath F, Spahn GH, et al. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. *Lancet*. 2019;393:2201–2212.
89. Rossler J, Hegemann I, Schoenrath F, et al. Efficacy of quadruple treatment on different types of pre-operative anaemia: secondary analysis of a randomised controlled trial. *Anaesthesia*. 2020;75:1039–1049.
90. Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. *Lancet Haematol*. 2016;3:e415–e425.
91. Elhenawy AM, Meyer SR, Bagshaw SM, MacArthur RG, Carroll LJ. Role of preoperative intravenous iron therapy to correct anemia before major surgery: a systematic review and meta-analysis. *Syst Rev*. 2021;10:36.
92. Koch CG, Li L, Sun Z, et al. Magnitude of anemia at discharge increases 30-day hospital readmissions. *J Patient Saf*. 2017;13:202–206.
93. Trentino KM, Mace HS, Symons K, et al. Screening and treating pre-operative anaemia and suboptimal iron stores in elective colorectal surgery: a cost effectiveness analysis. *Anaesthesia*. 2020;76:357–365.
94. Trentino KM, Mace H, Symons K, et al. Associations of a preoperative anemia and suboptimal iron stores screening and management clinic in colorectal surgery with hospital cost, reimbursement, and length of stay: a net cost analysis. *Anesth Analg*. 2021;132:344–352.
95. Warner MA, Goobie SM. Preoperative anemia screening and treatment: is it worth the return on investment? *Anesth Analg*. 2021;132:341–343.
96. Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. *Ann Surg*. 2016;264:41–46.
97. McSorley ST, Anderson JH, Whittle T, et al. The impact of preoperative systemic inflammation on the efficacy of intravenous iron infusion to correct anaemia prior to surgery for colorectal cancer. *Perioper Med (Lond)*. 2020;9:17.
98. Ganz T. Anemia of inflammation. *N Engl J Med*. 2019;381:1148–1157.
99. Lasocki S, Asfar P, Jaber S, et al. Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial. *Crit Care*. 2021;25:62.
100. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. *Lancet*. 2021;397:233–248.
101. Wicinski M, Licznar G, Cadelski K, Kolnierzak T, Nowaczewska M, Malinowski B. Anemia of chronic diseases: wider diagnostics-better treatment? *Nutrients*. 2020;12:1784.
102. Ranucci M, Baryshnikova E, Castelvechio S, Pelissero G; Surgical and Clinical Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. *Ann Thorac Surg*. 2013;96:478–485.
103. Koch CG, Reineks EZ, Tang AS, et al. Contemporary bloodletting in cardiac surgical care. *Ann Thorac Surg*. 2015;99:779–784.
104. Shander A. Financial and clinical outcomes associated with surgical bleeding complications. *Surgery*. 2007;142:S20–S25.
105. Levy JH, Dutton RP, Hemphill JC III, et al. Multidisciplinary approach to the challenge of hemostasis. *Anesth Analg*. 2010;110:354–364.
106. Althoff FC, Neb H, Herrmann E, et al. Multimodal patient blood management program based on a three-pillar strategy: a systematic review and meta-analysis. *Ann Surg*. 2019;269:794–804.
107. Spahn DR, Muñoz M, Klein AA, Levy JH, Zacharowski K. Patient blood management: effectiveness and future potential. *Anesthesiology*. 2020;133:212–222.
108. Sazama K. The ethics of blood management. *Vox Sang*. 2007;92:95–102.
109. Meybohm P, Richards T, Isbister J, et al. Patient blood management bundles to facilitate implementation. *Transfus Med Rev*. 2017;31:62–71.
110. Shander A, Goobie SM, Warner MA, et al. Essential role of patient blood management in a pandemic: a call for action. *Anesth Analg*. 2020;131:74–85.
111. Gross I, Shander A, Sweeney J. Patient blood management and outcome, too early or not? *Best Pract Res Clin Anaesthesiol*. 2013;27:161–172.
112. Zacharowski K, Spahn DR. Patient blood management equals patient safety. *Best Pract Res Clin Anaesthesiol*. 2016;30:159–169.
113. SABM. What is Patient Blood Management? Society for the Advancement of Patient Blood Management. 2021. Accessed April 8, 2021. <https://www.sabm.org/>.
114. IFPBM. What is Patient Blood Management? International Foundation for Patient Blood Management. 2016. Accessed February 22, 2021. <https://www.ifpbm.org/index.php>.
115. WHO. WHO Action framework to advance universal access to safe, effective and quality assured blood products 2020–2023. WHO. 2020. Accessed December 18, 2020. <https://www.who.int/publications/i/item/action-framework-to-advance-uas-blood-prods-978-92-4-000038-4>.
116. AABB. Patient Blood Management. AABB. 2021. Accessed April 8, 2021. <https://www.aabb.org/newsresources/resources/patient-blood-management>.
117. Patient Blood Management 2018 Survey. Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee 2021. Accessed April 8, 2021. <https://www.transfusinguidelines.org.uk/transfusion-committees/national-blood-transfusion-committee/patient-blood-management>.

118. NBA. The National Patient Blood Management Implementation Strategy 2017–2021. National Blood Authority (Australia). 2017. Accessed December 31, 2021. <https://www.blood.gov.au/implementing-pbm>.
119. National Blood Authority (Australia). Patient Blood Management Guidelines: Modules 1–6. 2013–2016. Accessed March 2020. <https://www.blood.gov.au/pbm-guidelines>.
120. Australian Commission on Safety and Quality in Health Care. What is Patient Blood Management? 2016. Accessed December 31, 2021. <https://www.safetyandquality.gov.au/national-priorities/pbm-collaborative/what-is-patient-blood-management>
121. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1545–1602.
122. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017;390:1211–1259.
123. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392:1789–1858.
124. Camaschella C. Iron deficiency. *Blood*. 2019;133:30–39.
125. Mansour D, Hofmann A, Gemzell-Danielsson K. A review of clinical guidelines on the management of iron deficiency and iron-deficiency anemia in women with heavy menstrual bleeding. *Adv Ther*. 2021;38:201–225.
126. Critchley HOD, Munro MG, Shakur-Still H, Roberts I. Menstruation should not be overlooked in control of anaemia. *Lancet*. 2021;397:26.
127. Althoff FC, Neb H, Herrmann E, et al. Multimodal patient blood management program based on a three-pillar strategy: a systematic review and meta-analysis. *Ann Surg*. 2019;269:794–804.
128. Frietsch T, Shander A, Faraoni D, Hardy JF. Patient blood management is not about blood transfusion: it is about patients' outcomes. *Blood Transfus*. 2019;17:331–333.

CONTRIBUTORS

Hans Gombotz, MD (Department of Anesthesiology and Intensive Care, General Hospital Linz, Austria), Jeffrey Hamdorf, MD, PhD (Medical School and Division of Surgery, Faculty of Medicine and Health Sciences, The University of Western Australia, Perth, Western Australia, Australia; Department of Anesthesiology, University Hospital Zurich, Zurich, Switzerland; Clinical Training and Evaluation Centre [CTEC], The University of Western Australia, Perth, Australia), James Isbister, MD (International Foundation for Patient Blood Management, Basel, Switzerland; Department of Haematology and Transfusion Medicine, Sydney Medical School, Royal North Shore Hospital of Sydney, Sydney, Australia), Mazyar Javidrooz, MD, PhD (Department of Anesthesiology, Critical Care and Hyperbaric

Medicine, Englewood Health, Englewood, New Jersey; M. Javidrooz has been a consultant for SABM and Gauss Surgical), Hongwen Ji, MD (Department of Blood Transfusion and Anesthesiology, Fuwai Hospital, Beijing, China), Tae-Yop Kim, MD, PhD (Department of Anesthesiology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea), Young-Woo Kim, MD (Division of Colorectal Surgery, Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea; Big Data Research Group, Yonsei University Wonju College of Medicine, Wonju, Korea), Ananthi Krishnamoorthy, MD (Department of Rehabilitation Medicine, Hospital Raja Permaisuri Bainun, Ipoh, Malaysia), Michael F. Leahy, MBChB (Department of Haematology, Royal Perth Hospital, Perth, Western Australia, Australia; Department of Anesthesiology, University Hospital Zurich, Zurich, Switzerland; School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia; PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Western Australia, Australia; M. F. Leahy has received honorarium from Vifor Pharma), Jong-Hoon Park, MD, PhD (Department of Orthopaedic Surgery, Anam Hospital, Korea University College of Medicine, Seoul, South Korea), Jacob Raphael, MD (Society of Cardiovascular Anesthesiologists [SCA] Patient Blood Management Committee, East Dundee, Illinois; Department of Anesthesiology, University of Virginia Medical Center, Charlottesville, Virginia), Jim Reagor, MPS, CCP, FPP (Department of Cardiovascular Perfusion, Cincinnati Children's Hospital, Cincinnati, Ohio), Charles-Marc Samama, MD, PhD (Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis [NATA], Paris, France; Department of Anaesthesia, Intensive Care and Perioperative Medicine, GHU AP-HP, Centre - Université de Paris - Cochin Hospital, Paris, France; C.-M. Samama has received consulting fees from LFB and Octapharma), Jameela Sathar, MD (Department of Haematology, Hospital Ampang, Selangor, Malaysia; Clinical Trial Unit, Clinical Research Centre, Ministry of Health, Ampang, Selangor, Malaysia), Jackie Thomson, MBChB (South African National Blood Service, Johannesburg, South Africa), Pierre Tibi, MD (Society for the Advancement of Patient Blood Management [SABM], Mount Royal, New Jersey; Department of Cardiovascular Surgery, Yavapai Regional Medical Center, Prescott, Arizona), Kevin Trentino, MPH, PhD (cand) (Medical School and Division of Surgery, Faculty of Medicine and Health Sciences, The University of Western Australia, Perth, Western Australia, Australia; Department of Anesthesiology, University Hospital Zurich, Zurich, Switzerland), Sigismond Lasocki, MD, PhD (Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis [NATA], Paris, France; Department of Anesthesiology and Critical Care, University of Angers, Angers, France).